BMS-310705 Bristol-Myers Squibb/GBF.
Bristol-Myers Squibb, in collaboration with the German Research Centre for Biotechnology, is developing BMS-310705, an epothilone analog, for the potential treatment of cancer. By April 2002, phase I trials of BMS-310705 were underway.
Kolman
Ada
A
Department of Molecular Biology and Functional Genomics, Stockholm University, SE-106 91 Stockholm, Sweden. ada.kolman@telia.com
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic / Q000379:methods; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D034261:Epothilones / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans
D000970:Antineoplastic Agents; C478223:BMS 310705; D015507:Drugs, Investigational; D034261:Epothilones